These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 7508623)

  • 1. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
    Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75).
    Gonzalez-Barcena D; Vadillo Buenfil M; Garcia Procel E; Guerra-Arguero L; Cardenas Cornejo I; Comaru-Schally AM; Schally AV
    Eur J Endocrinol; 1994 Sep; 131(3):286-92. PubMed ID: 7921214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Cortez-Morales A; Fuentes-Garcia M; Cardenas-Cornejo I; Comaru-Schally AM; Schally AV
    Urology; 1995 Feb; 45(2):275-81. PubMed ID: 7531902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
    Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
    Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).
    Pinski J; Schally AV; Yano T; Groot K; Srkalovic G; Serfozo P; Reissmann T; Bernd M; Deger W; Kutscher B
    Int J Pept Protein Res; 1995 May; 45(5):410-7. PubMed ID: 7591480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.
    Mathé G; Schally AV; Comaru-Schally AM; Mauvernay RY; Vovan ML; Machover D; Misset JL; Court B; Bouchard P; Duchier J
    Prostate; 1986; 9(4):327-42. PubMed ID: 2947053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
    Bokser L; Srkalovic G; Szepeshazi K; Schally AV
    Neuroendocrinology; 1991 Aug; 54(2):136-45. PubMed ID: 1662786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
    Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
    J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Ureta-Sanchez S; Berea Dominguez H; Graef-Sanchez A; Becerril Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1985; 7(1):21-30. PubMed ID: 2934692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
    Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
    Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men.
    Behre HM; Böckers A; Schlingheider A; Nieschlag E
    Clin Endocrinol (Oxf); 1994 Feb; 40(2):241-8. PubMed ID: 8137524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats.
    Pinski J; Yano T; Janaky T; Nagy A; Juhasz A; Bokser L; Groot K; Schally AV
    Int J Pept Protein Res; 1993 Jan; 41(1):66-73. PubMed ID: 8436447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
    Halmos G; Schally AV; Pinski J; Vadillo-Buenfil M; Groot K
    Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2398-402. PubMed ID: 8637885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
    Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advanced cancer of the prostate. Treatment with an LH-RH agonist, D-Trp-6-LH-RH].
    Mathé G; Misset JL; Vovan ML; Machover D
    Bull Cancer; 1986; 73(1):31-5. PubMed ID: 2430652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
    Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
    J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.